[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 326
Citations 0
News From the Food and Drug Administration
June 16, 2015

More Protection Against Plague

JAMA. 2015;313(23):2312. doi:10.1001/jama.2015.6117

Moxifloxacin, a fluoroquinolone antibacterial agent, has been approved under the FDA’s Animal Efficacy Rule to treat patients with plague.

A rare and potentially fatal illness, plague is caused by infection with the Yersinia pestis bacteria, also considered a potential bioterrorism agent. The 3 most common forms of plague are bubonic (lymph node infection), pneumonic (lung infection), and septicemic (blood infection) (http://1.usa.gov/1JwilK9).

First Page Preview View Large
First page PDF preview
First page PDF preview
×